T Rowe Price International Equity ETF(TOUS.US)

Company Encyclopedia
View More
name
T Rowe Price International Equity ETF
TOUS.US
News
View More

Jacobio Pharma Signs Agreement With AstraZeneca On Pan-KRAS Inhibitor JAB-23E73

Jacobio Pharma has signed a strategic agreement with AstraZeneca for its Pan-KRAS inhibitor, JAB-23E73. AstraZeneca gains exclusive rights outside China, while both companies will collaborate within China. Jacobio receives $100 million upfront and potential milestone payments up to $1.915 billion. AstraZeneca will handle development and commercialization outside China. JAB-23E73 targets KRAS mutations, currently in Phase I trials. Jacobio plans further KRAS pathway exploration and immuno-oncology programs.

rttnews·
UK
AZN
0.00%
US
AZN
+0.68%
rttnews·
UK
AZN
0.00%
US
AZN
+0.68%

FDA Approves AstraZeneca and Daiichi Sankyo's ENHERTU Regimen for HER2-Positive Metastatic Breast Cancer

AstraZeneca and Daiichi Sankyo's ENHERTU regimen for HER2-positive metastatic breast cancer has been approved by the FDA in the US. The approval was expedited under the FDA's RTOR initiative and reviewed under Project Orbis. AstraZeneca will pay Daiichi Sankyo a $150 million milestone following this approval. The news was generated by Public Technologies using AI and is based on AstraZeneca's original content.

Reuters·
US
AZN
+0.68%
UK
AZN
0.00%
US
DSNKY
+1.05%
Reuters·
US
AZN
+0.68%
UK
AZN
0.00%
US
DSNKY
+1.05%

AstraZeneca Showcases New Hematology Data with 65 Abstracts at ASH 2025

AstraZeneca will present 65 abstracts at the ASH 2025, showcasing data on eight medicines, including surovatamig and AZD0120. Key presentations involve trials for follicular lymphoma and multiple myeloma. The event is scheduled for December 6-9, 2025.

Reuters·
UK
AZN
0.00%
US
AZN
+0.68%
Reuters·
UK
AZN
0.00%
US
AZN
+0.68%

AstraZeneca to expand biomanufacturing in Maryland, US

AstraZeneca has announced a $2bn investment to expand its biomanufacturing in Maryland, US. The plan includes expanding the Frederick biologics manufacturing facility and constructing a new plant in Gaithersburg, supporting 2,600 jobs. The Frederick site will nearly double its capacity, while the Gaithersburg facility will develop new molecules for clinical trials. Both sites will use advanced AI and automation. This investment is part of AstraZeneca's $50bn initiative announced in 2025, aimed at strengthening the US medicines supply chain and accelerating access to therapies.

Pharmaceutical Technology·
US
AZN
+0.68%
Pharmaceutical Technology·
US
AZN
+0.68%

19:01 ET Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology

Harbour BioMed has advanced its global strategic collaboration with AstraZeneca to develop next-generation biotherapeutics in oncology. The partnership, established in March 2025, focuses on antibody-drug conjugates and T cell engagers. AstraZeneca will nominate discovery programs annually, with Harbour BioMed eligible for fees, milestone payments, and royalties. The collaboration leverages Harbour BioMed's proprietary antibody platforms to address unmet medical needs.

prnewswire·
UK
AZN
0.00%
US
AZN
+0.68%
prnewswire·
UK
AZN
0.00%
US
AZN
+0.68%
© 2026 Longbridge｜Disclaimer